blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4251167

EP4251167 - ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  01.09.2023
Database last updated on 03.10.2024
FormerThe international publication has been made
Status updated on  04.06.2022
Formerunknown
Status updated on  22.02.2022
Most recent event   Tooltip08.05.2024New entry: Loss of particular rights: legal effect 
Applicant(s)For all designated states
Deciphera Pharmaceuticals, LLC
200 Smith Street
Waltham, MA 02451 / US
[2023/40]
Inventor(s)01 / FLYNN, Daniel L.
Waltham, Massachusetts 02451 / US
 [2023/40]
Representative(s)Marks & Clerk LLP
15 Fetter Lane
London EC4A 1BW / GB
[2023/40]
Application number, filing date21856943.224.11.2021
[2023/40]
WO2021US60747
Priority number, dateUS202063118512P25.11.2020         Original published format: US 202063118512 P
[2023/40]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022115549
Date:02.06.2022
Language:EN
[2022/22]
Type: A1 Application with search report 
No.:EP4251167
Date:04.10.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 02.06.2022 takes the place of the publication of the European patent application.
[2023/40]
Search report(s)International search report - published on:EP02.06.2022
ClassificationIPC:A61K31/5377, A61P31/14
[2023/40]
CPC:
A61K31/5377 (EP,US); A61P31/14 (EP,US); Y02A50/30 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/40]
Extension statesBA20.06.2023
ME20.06.2023
Validation statesMA20.06.2023
TN20.06.2023
TitleGerman:ANTIVIRALE WIRKUNG VON VPS34-INHIBITOREN[2023/40]
English:ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS[2023/40]
French:ACTIVITÉ ANTIVIRALE D'INHIBITEURS DE VPS34[2023/40]
Entry into regional phase20.06.2023National basic fee paid 
20.06.2023Designation fee(s) paid 
20.06.2023Examination fee paid 
Examination procedure20.06.2023Amendment by applicant (claims and/or description)
20.06.2023Examination requested  [2023/40]
20.06.2023Date on which the examining division has become responsible
16.01.2024Loss of particular rights, legal effect: Claims
06.02.2024Despatch of communication of loss of particular rights: Claims {1}
Fees paidRenewal fee
20.06.2023Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XDY]WO2017140841  (SPRINT BIOSCIENCE AB [SE]) [XD] 1-4,18,41,42 * page 9, line 3-19 and line 29-31; page 16, line 3-9; page 17, line 12-27; page 18, line 11-23 * [Y] 1-58;
 [E]WO2022015823  (UNIV GEORGIA STATE RES FOUND [US]) [E] 1-17,41-58* page 1, line 20 - page 2, line 18 *;
 [Y]  - Silvas Jesus A. ET AL, "Inhibitors of VPS34 and lipid metabolism suppress SARS-CoV-2 replication", bioRxiv, doi:10.1101/2020.07.18.210211, (20200720), URL: https://www.biorxiv.org/content/10.1101/2020.07.18.210211v1.full, (20220222), XP055894508 [Y] 1-58 * page 4, line 69-88; page 9 line 195 - page 10, line 210; page 11, line 232 - page 14, line 306; figure 2, 4, 5 *

DOI:   http://dx.doi.org/10.1101/2020.07.18.210211
 [Y]  - DANILOSKI ZHARKO ET AL, "Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells", CELL, ELSEVIER, AMSTERDAM NL, vol. 184, no. 1, doi:10.1016/J.CELL.2020.10.030, ISSN 0092-8674, (20201024), page 92, (20201024), XP086441574 [Y] 1-58 * page 97 right-hand column, paragraph; page 102 right-hand column paragraph 2; figures 4E and S4 *

DOI:   http://dx.doi.org/10.1016/j.cell.2020.10.030
by applicantWO2017140841
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.